Drugs facing NCE-1 in 2028
1. List of Fetroja drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(10 years from now) | |
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| New Indication (I) | Sep 25, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 2028-11-14
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
FETROJA family patents
10
Japan
4
Korea, Republic of
4
European Union
3
Spain
3
China
3
Hungary
3
United States
3
Lithuania
2
Australia
2
EA
2
Croatia
2
Canada
2
Denmark
2
Malaysia
2
Portugal
2
Poland
2
Morocco
2
Slovenia
2
Mexico
2
Brazil
2
RS
2
Taiwan
1
Colombia
1
Israel
1
Netherlands
1
New Zealand
1
Peru
1
Costa Rica
1
Chile
1
ME
1
Cyprus
1
Ukraine
1
Philippines
1
Norway
1
San Marino
1
South Africa
2. List of Recarbrio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 2028-07-16
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...
Dosage: POWDER;INTRAVENOUS
RECARBRIO family patents
4
United States
3
Japan
3
Lithuania
2
Ecuador
2
Croatia
2
Korea, Republic of
2
Netherlands
2
Denmark
2
Spain
2
Cyprus
2
Portugal
2
Poland
2
Hong Kong
2
Slovenia
2
RS
2
China
2
Hungary
2
European Union
1
Colombia
1
Luxembourg
1
Australia
1
Israel
1
Dominican Republic
1
Canada
1
New Zealand
1
Honduras
1
Malaysia
1
Costa Rica
1
Nicaragua
1
ME
1
Ukraine
1
Russia
1
Morocco
1
Norway
1
Mexico
1
Brazil
1
South Africa
3. List of Xenleta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8153689 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(4 years from now) | |
| US8071643 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Jan, 2029
(5 years from now) | |
| US9120727 | NABRIVA | Process for the preparation of pleuromutilins |
May, 2031
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 2028-08-19
Market Authorisation Date: 19 August, 2019
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
XENLETA family patents
15
United States
6
European Union
4
Denmark
4
Spain
4
Portugal
4
Japan
4
China
3
Austria
3
Poland
3
Hungary
2
Australia
2
EA
2
Israel
2
Croatia
2
Korea, Republic of
2
Canada
2
New Zealand
2
Tunisia
2
Malaysia
2
Ukraine
2
Morocco
2
Hong Kong
2
Slovenia
2
Brazil
2
South Africa
2
Taiwan
1
Netherlands
1
Cyprus
1
Singapore
1
Norway
1
Mexico
1
Turkey
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic